Background The medical transition undergone by a transgender person may influence their risk of breast or reproductive cancer.
Introduction
A transgender (trans) woman is a woman who was assigned male at birth, and a transman is a man who was assigned female at birth. It is recognised that trans people may identify as non-binary (not identifying with either aspect of the gender binary of male and female). However, current medical literature tends to use only the terms 'transmen' and 'transwomen' when describing the trans population. Someone who does identify with the sex they were assigned at birth can be known as cisgender (cis).
The stage and kind of medical transition undergone by a trans person can influence their risk of developing breast and reproductive cancers. Gender confirmation surgery involving the removal of potential reproductive cancer sites may eliminate the risk of certain reproductive cancers. A transwoman, for example, who has undergone a bilateral orchiectomy is no longer at risk of developing testicular cancer. The impact of gender-affirming hormones on breast and reproductive cancer risk is less clear. Exogenous hormones are known to play a role in breast and reproductive oncology in the cis population, as in the case of hormone replacement therapy (HRT) and increased breast cancer risk. 1 However, in the specific context of trans healthcare, the role (or lack of a role) of exogenous hormones in breast and reproductive cancer pathogenesis is uncertain.
This systematic review aimed to assess the prevalence of breast, ovarian, cervical, uterine, vaginal, neovaginal, testicular and prostate cancer in the trans population. It also aimed to compare the breast and reproductive cancer prevalence rates of trans people undergoing hormone therapy with those of trans people not undergoing hormone therapy, in order to elucidate any associations between genderaffirming hormones and breast/reproductive cancer risk.
Methods
The protocol of this systematic review is registered with PROSPERO (http://www.crd.york.ac.uk/PROSPERO/displa y_record.asp?ID=CRD42017059082). A separate systematic review will report on screening of breast and reproductive cancers in the trans population. Therefore, studies fitting this description will be excluded here. The review design did not include patient involvement or the use of core outcomes.
Research questions
The research questions addressed are:
What is the prevalence of breast and reproductive cancers in the trans population?
Is the use of gender-affirming hormones associated with an altered risk of breast or reproductive cancers in the trans population?
In this systematic review, the trans population was defined as anyone who identifies as trans regardless of stage of medical transition. Studies involving transmen and transwomen were examined separately. In addition to breast cancer, the reproductive cancers examined were ovarian, cervical, uterine, vaginal, neovaginal, testicular and prostate cancer.
Search strategies
In February 2017, the following databases were searched: MEDLINE, Embase, PsycINFO, The Cochrane Library, and Web of Science. No restrictions on language, setting or date of publication were applied. Search strategies (Appendix S1) were tailored to each database to ensure appropriate use of Medical Subject Headings (MeSH) terms. In addition, the reference lists of included articles were read to identify any further relevant studies.
Eligibility of studies
The title and abstract of all articles returned by the search strategies were screened by two authors (R.J. and Z.E.C.) for relevance and duplicates. All remaining articles were read in full, and inclusion and exclusion criteria were applied (Table S1 ). Disagreement about inclusion verdict was resolved by the senior researcher (S.C.).
Assessment of study quality
Study quality was independently assessed by the two reviewers (R.J. and Z.E.C.) using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) protocol.
Analysis
Studies were categorised, collated and analysed by study population, i.e. transmen/transwomen, and then by type of cancer. There was not sufficient crossover between studies to merit a meta-analysis.
Results

Quantity
The systematic literature search yielded 228 articles and a further 29 were identified by screening the bibliographies of included studies. Title and abstract screening excluded 163 duplicate and irrelevant studies. A further 51 articles were excluded following the application of inclusion and exclusion criteria, leaving 43 studies that were included in this systematic review.
Of these included studies, 33 were case reports, five were cohort (reporting on three studies), three were case-control (reporting on two studies) and two were cross-sectional. No randomised control trials were identified. Figure 1 shows the number and type of studies addressing each cancer.
The PRISMA flow diagram can be viewed as Figure S1 , and the PRISMA checklist as Figure S2 . A list of studies excluded can be found in Table S2 . Details of the included studies (summary of findings and overall quality rating) can be found in Table S3 , and details of all reported individual cancer cases in Table S4 .
Quality
The overall quality of studies was very low to low, owing to study design and small sample size. There were four cohort studies of moderate quality due to larger sample sizes. Most studies were case reports, the evidence quality of which is extremely low due to a susceptibility to publication bias and over-interpretation, and the provision of data solely for individuals. All other studies were observational, with most being retrospective, associated with a significant risk of observer bias. The lack of control for confounding factors is particularly limiting when examining the risk factors for cancer, which can be multifactorial.
Estimation of prevalence
The evidence identified was not suited to the planned prevalence estimation. Table 1 provides a summary of the total number of breast and reproductive cancer cases identified from the included studies.
Cancers in transmen
Breast cancer Case-control studies. Breast biopsies from 23 transmen after 18-24 months of testosterone therapy were compared with breast biopsies of 10 ciswomen. No cancer cases were found. 2 Cohort studies. Four retrospective cohort studies were published. [3] [4] [5] [6] One study which analysed breast biopsies from 112 transmen after at least 6 months of androgens did not identify any malignancy or atypical hyperplasia in their breast tissue. 7 The other studies were of higher quality due to larger sample sizes. Together, they examined 54 years of clinical data and identified eight breast cancer cases in transmen. [4] [5] [6] Gooren et al. 4 calculated an incidence rate of 5.9 per 100 000 person-years in the transmen, which equated to an expected incidence for breast cancer in cismen (1.2 per 100 000 person-years) and a lower than expected incidence for breast cancer in ciswomen (170 per 100 000 person-years). Brown and Jones 5 calculated an incidence rate of 4.3 per 100 000 person-years for transmen (no significant difference from expected rates in cismen).
Cross-sectional studies and case reports. Five case reports [8] [9] [10] [11] [12] and one cross-sectional study 13 described breast cancer in transmen.
A total of 18 cases were reported: 38.9% of all cases were invasive ductal carcinomas, 11.1% tubular adenocarcinomas, 5.6% neuroendocrine carcinomas, and 33.3% did not specify cancer type. Fourteen cases reported details of estrogen receptor (ER) and progesterone receptor (PR) positivity: 85.7% were ER-positive and 71.4% were PRpositive. 4, 6, [8] [9] [10] [11] [12] Two cases provided details of androgen receptor (AR) positivity, with both testing positive. 10, 12 BRCA testing was performed in three cases; all tested negative. 9, 11 Thirteen transmen had been taking androgens for 1-15 years. 4, 6, [8] [9] [10] [11] [12] [13] Eight of these transmen had also undergone a mastectomy. [5] [6] [7] [8] [10] [11] [12] [13] All but one 8 of the cases outlined cancer treatment regimens. Treatment was reported to be successful in all these studies except for one transman who died of metastatic breast cancer 2 years after the initial diagnosis. 6 Six studies specified how androgen therapy continuation was affected by cancer treatment; in two cases it was halted, 12, 13 and in the remaining four it was recommenced. 6, 9, 11 In all but one 6 of these cases, the androgen dose was reduced. Ovarian cancer Cohort studies. The ovaries of 112 transmen were retrospectively analysed after at least 6 months of androgen administration. No ovarian cancer was reported.
3
Cross-sectional studies and case reports. Five cases of ovarian cancer were reported, three in case reports 7, 14 and two in a cross-sectional study. 13 Three of these transmen had taken gender-affirming hormones for 1-18 years. 7, 14 In one case, gender-affirming hormones were discontinued following diagnosis due to AR positivity of the cancer.
14 One case report recommended simultaneous salpingo-oophorectomy for any transman undergoing gender-affirming hysterectomy, 7 whereas the other case report contradicted this by stating that there is insufficient evidence linking exogenous androgens and ovarian malignancy.
14 Uterine and cervical cancer Cohort studies. The genital tract histopathology of 112 transmen after at least 6 months of androgen administration was retrospectively analysed. One sample displayed endometrial hyperplasia with a small focus of adenocarcinoma. No cervical cancer was found, but one sample displayed cervical dysplasia. Cross-sectional studies and case reports. One case of uterine cancer and three cases of cervical cancer were reported, three in individual case reports, 15, 16 and one in a cross-sectional study. 13 All transmen had taken gender-affirming hormones (duration of administration was not always clear). None of the studies reported on the human papillomavirus (HPV) status of the cancers.
Vaginal cancer
Case-control studies. Two case-control studies compared vaginal biopsies from 16 transmen undergoing androgen therapy with those of 32 ciswomen. No cases of vaginal cancer were found. 17, 18 One study reported that androgen therapy did not change AR density in the vaginal mucosa but did significantly increase AR density in stromal tissue. It also significantly increased AR protein expression but did not affect AR mRNA levels. 17 The other study reported thinned vaginal epithelium with reduced proliferation in transmen. 18 Case reports. One case of vaginal cancer was reported which was HPV-positive. The transman had not taken gender-affirming hormones. 19 
Cancers in transwomen
Breast cancer Cohort studies. Three cohort studies were published. [4] [5] [6] Two cases were retrospectively identified in a cohort of 2307 transwomen, with an incidence rate of 4.1 per 100 000 personyears (close to the expected rate in cismen and significantly lower than the expected rate in ciswomen). 4 Three cases were retrospectively identified in a cohort of 5135 trans people, with an incidence rate of 0.09 per 100 000 person-years (no significant difference from expected rates). 5, 6 Case reports. Twelve case reports identified 15 cases of breast cancer in transwomen. 11, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Of the 20 reported cases of breast cancer, 50% were invasive ductal carcinomas, 15% adenocarcinomas, 10% ductal carcinomas, 10% unspecified breast carcinomas, 5% ductal carcinoma in situ, 5% secretory carcinomas and the primary tumour was unconfirmed in 5%. Seventeen cases outlined ER positivity; 52.9% tested positive. 4, 6, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Eleven studies reporting on 15 cases addressed PR positivity; 40% tested positive. 4, 6, 21, [23] [24] [25] [26] [27] [28] [29] [30] Two studies addressed AR positivity, with one case testing positive. 24, 31 BRCA testing was performed in five cases of breast cancer: four tested negative 11, 26, 28, 29 and one positive for BRCA2 mutation. 30 All but one of the transwomen had taken gender-affirming hormones before diagnosis, with administration duration ranging 6-37 years. Six transwomen had undergone gender-affirming breast surgery. 20, 23, 24, 26, 27 Eight studies described how hormone continuation was affected by cancer diagnosis; five transwomen discontinued, 11, 29, 30 one was advised to discontinue 28 and two continued. 22, 27 Sixteen studies described treatment regimens for breast cancer; one transwoman died before treatment commenced, 4 one discharged herself before treatment began 24 and 14 underwent treatment. 4, 11, 21, 22, 24, [26] [27] [28] [29] [30] Disease recurrence or progression was reported in six cases, with five of these transwomen dying from metastasis 6, 11, 20 and one from an antidepressant (doxepin) overdose. 25 Four cases reported no recurrence. 4, 11, 12, 21 One report described a 34-year-old transwoman diagnosed with a BRCA2 mutation resulting in changes to her use of gender-affirming hormones. She continued her topical estrogen but halted her oral antiandrogen. 31 Neovaginal cancer Case reports. Two cases of squamous-cell carcinomas of former penile skin were reported. 32, 33 One was HPV-positive with no previous gender-affirming hormone administration reported 32 and the other was HPV-negative with 33 years of gender-affirming hormone therapy. 33 Testicular cancer Case reports. There was one case of a transwoman diagnosed with an ER-negative intratubular germ cell carcinoma in situ who had been taking gender-affirming hormones for 2 years. 34 Prostate cancer Cohort studies. Gooren and Morgentaler 35 retrospectively examined 1975-2006 data regarding 2306 transwomen and identified one case. The incidence rate was 0.04% (lower than the expected rate for cismen).
Cross-sectional studies. One study involved the analysis of prostate biopsies from nine transwomen who underwent gender-affirming hormone therapy and orchiectomy, digital rectal examinations and ultrasounds. The prostates displayed decreased size but a well-preserved zonal architecture. No prostate cancer cases were found. 36 Case reports. Eight case reports have been published, including a report covering Gooren and Morgentaler's case. [37] [38] [39] [40] [41] [42] [43] [44] The average diagnosis age was 64.8 years. In all, 62.5% were prostatic adenocarcinomas and 37.5% were unspecified. Six transwomen had received hormones for 10-41 years, [39] [40] [41] [42] [43] [44] and six had undergone gender confirmation surgery including orchiectomy, with the mean age for orchiectomy being 48 years. [37] [38] [39] [40] [41] [42] Five studies described hormone use after diagnosis, with two transwomen discontinuing 29, 44 and three continuing hormone use. [40] [41] [42] Follow-up data were provided by five studies: three transwomen showed no evidence of recurrence, 39, 41, 44 recurrence occurred in one transwoman, 43 and one transwoman died of metastatic disease. 42 
Discussion
Main findings
Evidence relating to breast and reproductive cancers in the trans population is limited and insufficient to estimate cancer prevalence. Low-quality evidence presented by a small number of studies and consisting of incidence rates and histopathological findings does not suggest that there is an increased risk of breast or reproductive cancers associated with the use of gender-affirming hormones.
Strengths and limitations
This is the first review to consider the risk of breast and all reproductive cancers associated with gender-affirming hormones. Prospective registration of the review protocol with PROSPERO was a strength, as were the individually designed search strategies to maximise the sensitivity of the literature search.
The review was limited by a lack of clinical and epidemiological data for prevalence estimation or for further analysis investigating an association between gender-affirming hormones and breast/reproductive cancer.
A unique limitation was the varying language used to describe the trans population. Care was taken to examine each study's terminology and accurately classify according to the gender binary of transmen and transwomen. This binary was adopted to match the review language with that of current literature but with the awareness that not all trans people are represented by it. Future research should be more inclusive of non-binary genders.
Articles screened were often excluded because they lacked data relating specifically to trans people. This occurred frequently in studies addressing the LGBT (lesbian, gay, bisexual, transgender) population but with few trans participants. The results of such studies were presented without distinction between trans and cis people, as all participants were represented by the LGBT acronym. This increased the number of articles that appeared eligible based on title and abstract but were ineligible on full screening.
Interpretation
Studies in the cis population examining the association between exogenous or high level endogenous hormones and breast/reproductive cancer risk may provide indirect evidence of a potential association between these cancer risks and gender-affirming hormones.
The Million Women Study reported an association between all forms of hormone replacement therapy (HRT) and increased breast cancer risk in ciswomen. Combined formulations of estrogens and progestogens showed a greater increase than estrogen-only HRT. Risk was further increased in ciswomen who used HRT for more than 10 years. 1 The gender-affirming hormones available to transwomen are combinations of estrogens and antiandrogens which may be used continuously and indefinitely with routine hormone level checks; gender-affirming estrogen administration most closely resembles estrogen-only HRT taken for many years. 45 However, the endogenous hormonal environment into which exogenous estrogen is introduced is different from that of HRT, as is the breast tissue which stands to be affected. The accurate estimation of the breast cancer risk of gender-affirming estrogen in transwomen therefore requires more specific investigation.
The role of endogenous androgens in breast cancer development in ciswomen is a current area of research, and the effect of exogenous androgen administration by transmen on breast cancer risk is relevant to and impacted by such research. Increased androgen levels have been observed in postmenopausal ciswomen with breast cancer. 46 Although no correlation between androgen levels and breast cancer risk has been found in ciswomen overall, high levels in premenopausal women have been positively associated with breast cancer risk, especially ER-and PR-positive breast cancer. 47 Most reported breast cancer cases in transmen have been ER-and PR-positive. In contrast, it has also been suggested that high levels of androgens are protective against breast cancer in premenopausal ciswomen and carcinogenic in postmenopausal ciswomen. 48 If this is the case, it has implications for gender-affirming androgens in transmen: are they safe before menopause or oophorectomy but dangerous afterwards?
There is evidence of an association between increased breast cancer risk in cismen and high estrogen levels, for example due to Klinefelter's syndrome. 49 The mean age of breast cancer diagnosis in cismen is 71 years, with 90% of these being ER-positive. 50 The mean age of breast cancer diagnosis in transwomen (as calculated here from all reported cases) is 50 years, with 53% of these being ERpositive. This suggests that the pathogenesis of breast cancer in transwomen may differ from that in cismen. However, this is based on 18 reported cases, significantly limiting the strength of any conclusions.
Guidance for gender-affirming hormones recommends evaluation of potential impact on existing medical conditions before commencement, followed by long-term monitoring of hormone levels. 45 Clinical assessment of personal and family history of breast/reproductive cancer should be incorporated in this evaluation and re-addressed in followup consultations. There is currently no evidence to support routine BRCA testing in the trans population and so it is recommended that testing follows national testing criteria as in the cis population. There is no existing guidance regarding gender-affirming hormone use in individuals diagnosed with cancer or following remission 45 and this review highlighted uncertainties in this area of clinical practice. In the context of HRT in ciswomen, guidance advises against administration in cases of active breast cancer or a history of breast cancer. 51 Clinicians should communicate the absence of robust evidence showing the impact of gender-affirming hormone continuation on cancer prognosis when supporting individuals in weighing up the risk and benefits of starting or continuing gender-affirmation hormone therapy.
Ciswomen are currently only offered estrogen-only HRT if they have undergone a hysterectomy, 52 as unopposed exogenous estrogen action in the uterus significantly increases endometrial cancer risk in postmenopausal ciswomen. 53 This carries potential relevance for transmen who retain their uterus, as gender-affirming androgens are partially aromatised to estrogen. To confuse matters, there is also evidence that androgens can exert an antiproliferative role in the endometrium, 54 which would tend towards a potential protective effect of androgen therapy on the endometrium of transmen. However, endogenous testosterone levels in postmenopausal and premenopausal ciswomen have been positively associated with cervical cancer. 55 Although these findings cannot be immediately applied to the unique endocrine environment of transmen taking gender-affirming hormones, they may indicate the potential for gender-affirming androgens to act as hormone modulators in uterine and cervical cancer pathogeneses.
Data regarding prostate cancer in transwomen provide interesting contributions to discussion of androgens and prostate cancer risk. Orchiectomy in early life (e.g. in eunuchs) has been associated with protection from prostate cancer, 56 and antiandrogens are a common treatment for prostate cancer. 57 However, prostate cancer development in transwomen following orchiectomy indicates that androgen withdrawal by orchiectomy does not invariably remove the potential for prostatic malignancy. Malignancy may have begun to develop in the prostates of these transwomen before orchiectomy (the mean age of orchiectomy was 48 years). It may be possible that androgens were not involved in the pathogenesis of prostate cancer and that estrogen instead played a role. In one study's analysis of prostate tumours, abnormal ER expression was positively associated with androgen withdrawal-resistant prostate cancer. 58 In contrast, a study using human cell lines found that ER-b agonists could be used with androgen suppressors to prevent the progression of advanced prostate cancer to castration-resistant prostate cancer. 59 Transwomen should constitute a key population of interest in this ongoing research, first and foremost because they are currently underserved but also because of their unique long-term androgen deprivation and estrogen supplementation.
Conclusions
Surveillance data on the safety of gender-affirming hormones regarding breast and reproductive cancer risk are needed to inform clinical recommendations. Standardised reporting of information (e.g. on cancer receptor status, hormone dose, route and period of exposure) and core outcomes should facilitate data collection and analysis. Epidemiological study of the trans population is intrinsically limited by the absence of a reliable method of counting the general trans population. 60 A better understanding of breast/reproductive cancer prevalence would be enabled by improvements in the general epidemiological study of the trans population.
Future research should utilise large-scale prospective studies with extended periods of follow up of trans individuals using gender-affirming hormones to identify potential long-term health impacts, including breast/reproductive cancer risk. Database (case-control) studies examining risk factors for these cancers should also take into consideration the use of gender-affirming hormones as a possible risk factor. A potential challenge for such studies is the fluency of gender recognition in national records. In the NHS, patients can request that the sex on their medical record be changed without a Gender Recognition Certificate or an updated birth certificate. 61 However, there is no guarantee that the recorded sex of every trans patient is altered, which may interfere with future database studies of the trans population.
Accurate, detailed collection and reporting of this information is essential to further knowledge in an understudied field, to aid the construction of evidence-based clinical guidelines, and ultimately to improve care provision for trans patients.
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